Question 780
A media company approves a portfolio strategy but individual workstreams begin without a shared component authorization baseline. The board expects current evidence of combined portfolio value, capacity and delivery impact. What is the most discriminating FIRST portfolio-level analysis to perform?
Explanation
Correct Answer
The controlled correction is: Compare the approved portfolio charter, roadmap sequencing and each component's authorized start conditions. It targets the reported requirement: A media company approves a portfolio strategy but individual workstreams begin without a shared component authorization baseline. The governing evidence supports this choice: Compare the approved portfolio charter, roadmap sequencing and each component's authorized start conditions.
Incorrect Answers
This addresses a different part of the workflow: use only the latest generic portfolio status color rather than inspect the specific decision data and assumptions for Initiate the authorized portfolio. The correction relevant to the described condition is compare the approved portfolio charter, roadmap sequencing and each component's authorized start conditions. A broad status indicator cannot resolve the specific criteria, risk, authority or dependency at issue.
This addresses a different part of the workflow: implement the proposed portfolio change first and investigate its prerequisites afterwards: Activate only the eligible components and publish a consistent portfolio initiation baseline for delivery managers. The correction relevant to the described condition is compare the approved portfolio charter, roadmap sequencing and each component's authorized start conditions.
This would broaden or bypass the intended change rather than address it safely: treat this post-decision success condition as sufficient evidence of the current root cause: An approved component roster, authorized start milestones and a reconciled portfolio baseline. The targeted action is compare the approved portfolio charter, roadmap sequencing and each component's authorized start conditions. A future acceptance condition does not substitute for an evidence-based initial diagnosis.